Genesis Medical Vision

Company Overview

Snapshot

Founded in November 2022 by Shay Cohen, Prof. Natan, and Iliya Kusner, Genesis Medical Vision operates with 1–10 employees. The company has raised $2.71M across 4 funding rounds from 2 investors. In July 2025, Genesis Medical Vision secured funding from The Siegel Group.

Business overview

Genesis Medical Vision is at the forefront of AI in radiology, developing a non-statistical, clinical AI-education methodology that mimics the logic and intuition of expert physicians. This approach requires minimal scans to achieve high accuracy with near-zero false positives. The company focuses on early detection of cancer, serving the healthcare industry with its core product G4Lungs, primarily in the United States and Europe.

Strategic signal

Genesis Medical Vision is actively engaged in a clinical trial for lung cancer screening, as evidenced by a LinkedIn update in July 2025. This initiative highlights the company's commitment to validating its AI-based diagnostic solutions in real-world clinical settings, signaling a strong push towards market adoption and regulatory approval for its technology.

Company Intelligence Q&A

What is Genesis Medical Vision's primary focus?

Genesis Medical Vision specializes in the early detection of cancer through its AI platform, utilizing a non-statistical, clinical AI-education methodology for radiology.

When was Genesis Medical Vision founded and by whom?

Genesis Medical Vision was founded in November 2022 by Shay Cohen, Prof. Natan, and Iliya Kusner.

Has Genesis Medical Vision received any grants?

In March 2024, Genesis Medical Vision secured a grant from the Israel Innovation Authority.

What is Genesis Medical Vision's current product development focus?

Genesis Medical Vision is currently conducting a clinical trial for lung cancer screening, aiming to develop and validate new methods or technologies in this critical area.